Androgen Deprivation Therapy (ADT) ADT, says Dr. Armstrong, was the subject of the very first Nobel Prize in Medicine related to cancer, won by Charles B. Huggins in 1966.

Androgen deprivation therapy is a lifesaving therapy used by thousands of men each year, but some patients are warning of ...

"Outside of metastatic castrate-resistant prostate cancer, both NCCN and ASCO do note that an osteoclast inhibitor (at ...

Androgen deprivation therapy was associated with a 72 percent higher risk of heart failure in a study of patients with prostate cancer. In The Journal of Clinical Pharmacology study, incidence ...

Androgen Deprivation Therapy (ADT) ADT, says Dr. Armstrong, was the subject of the very first Nobel Prize in Medicine related to cancer, won by Charles B. Huggins in 1966. [2] [3] ...

In this article, Sandy Srinivas, MD, discusses androgen deprivation therapy as a treatment for advanced prostate cancer and examines potential avenues for future research, ...

Androgen-deprivation therapy (ADT) is well established as the standard of care in metastatic prostate cancer (PCa) management; however, ADT has significant adverse effects (AEs) that must be ...

Among patients with metastatic hormone-sensitive prostate cancer, the treatment combination of Nubeqa (darolutamide) and androgen deprivation therapy (ADT) has reportedly displayed positive results ...

A meta-analysis showed risk for heart failure in men with prostate cancer receiving ADT was higher in Asian studies that in North American studies.

Purpose The potential association between androgen deprivation therapy (ADT) and cardiovascular mortality (CVM) remains controversial. This study assessed mortality outcomes in a large national ...